The role of chemotherapy in recurrent malignant gliomas: An overview

Cancer Investigation

Volumn 14, Issue 6, 1996, Pages 551-559

  Brandes, Alba Ariela ^a   Fiorentino, Mario V ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AZIRIDINYLBENZOQUINONE; BETA INTERFERON; CARMUSTINE; CHLORMETHINE; CISPLATIN; DIANHYDROGALACTITOL; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOTEMUSTINE; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; LONIDAMINE; MELPHALAN; MENOGARIL; MERCAPTOPURINE; METHOTREXATE; MITOLACTOL; MITOXANTRONE; NITROSOUREA DERIVATIVE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; THIOTEPA; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; GLIOMA; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030477277     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609076900     Document Type: Review

References (83)

1. Walker MD, Alexander E, Hunt WE: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative trial. J Neurosurg 49:333-343, 1978.
2. Walker MD, Green SB, Byar DP: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N Engl J Med 303:1323-1329, 1980.
3. Brant-Zawadzki M, Norman D: Magnetic Resonance Imaging of the Central Nervous System. New York, Raven Press, 1987.
4. Doyle WK, Budinger TF, Valk PE: Differentation of cerebral radiation necrosis from tumor recurrence by (18 F) FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 11:563-570, 1987.
5. Black KL, Hawkins RA, Kim KT: Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 71:342-345, 1989.
6. Karnofsky DA: Meaningful clinical classification of the therapeutic responses to anticancer drugs. Clin Pharmacol Ther 26:709-712, 1961.
7. Levin VA, Wilson CB, Crafts D: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumor. J Neurosurg 47:329-335, 1977.
8. McDonald DR, Cascino TL, Clifford S: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990.
9. Levin VA, Landhal H, Freeman-Dove M: The application of brain capillary permeability coefficient measurements to pathological conditions and the selections of agents which cross the blood brain barrier J Pharmacokin Biopharmaceut 4:499-503, 1976.
10. Weller R, Foy M, Cox S: The development and ultrastructure of the micro vasculature in malignant gliomas. Neuropathol Appl Neurobiol 3:307-322, 1977.
11. Yung WKA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42:992-998, 1982.
12. Ali Osman F: Drug resistance mechanisms: implications for chemotherapy for primary brain tumors both inherent and acquired. 15th Internatinal Cancer Congress Hamburg, August 16-22, 1990, abstract 25:27, 02.
13. Schold SC, Brent TB, Von Hoff E: O6-Alkylguanine DNA alkil-transferase and sensitivity to procarbazine in human brain tumor xenografts. J Neurosurg 70:573-577, 1989.
14. Ali-Osman F, Schofield D: Cellular and molecular studies in brain and nervous system oncology. Curr Opin Oncol 2:655-659, 1990.
15. Ali-Osman F, Stein DE, Renwick A: Glutathione content and glutathione-S-transferase expression in 1,3 bis (2-chloroethyl)-1-nitrosurea-resistant human: Malignant astrocytoma cell lines. Cancer Res 50:6976-6980, 1990.
16. Allalunis-Turner MJ, Day RS, Me Kean JDS, et al: Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. J Neuro-Oncol 11:157-160, 1991.
17. Osman FA: Improved nitrosourea-based brain tumor therapy by pretherapeutic determination of tumor glutathione (GSH) and glutathione-S-transferase. 15th Internatinal Cancer Congress. Hamburg, August 16-22, 1990, abstract 20:27, 05.
18. Scheck AC, Beikman MK, Korn MC, et al: Regional analysis of genes potentially involved in resistance to BCNU in human malignant gliomas. Barrow Neurological Institute, SJHMC, Phoenix, AZ 85013. Proc Am Assoc Cancer Res 32:358, 1991.
19. Wang AM, Elion GB, Friedman HS, et al: Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. Cancer Chemother Pharmacol 27:278-282, 1991.
20. Smith DC, Vixk NA, Trump DL, et al: Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Cancer Chemother Pharmacol 30:272-283, 1992.
21. Albain KS, Swinnen LJ, Ericksin LC, et al: Cisplatin preceded by concurrent cytarabine and hydroxyurea: A pilot study based on an in vitro model. Cancer Chemother Pharmacol 27:33-39, 1990.
22. Doz F, Berens ME, Spencer DR, et al: Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds. Cancer Chemother Pharmacol 28:308-312, 1991.
23. EORTC Brain Tumor Group: Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma: Final evaluation. Eur J Cancer 14:851-856, 1978.
24. Gregor A, Rampling R, Aapro M, et al: Phase II study of tauromustine in malignant glioma. Eur J Cancer 28:1959-1962, 1992.
25. Frenay M, Giroux B, Khoury S, et al: Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 27:852-855, 1991.
26. O'Reilly SM, Newlands ES, Glaser MG: Temozolamide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A:940-942, 1993.
27. Afra D: Vincristine therapy in malignant glioma recurrencies. Neurochirurgie 16:189-198, 1973.
28. Djerassi I, Kim JS, Kassarov A: High dose methotrexate with citrovorum factor in astrocytoma. Proc Ann Meet Am Soc Clin Oncol 7:314, 1988.
29. Rodriguez LA, Prados M, Silver P: Revaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours. Cancer 64:2420-2423, 1989.
30. Spence AM, Berger MS, Livingston RB, et al: Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloraethylnitrosourea failure. J Neuro-Oncol 12:187-191, 1992.
31. Kessinger A, Lemon HM, Foley JF: VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63:511-512, 1979.
32. Tirelli U, D'Incalci M, Canetta M: Etoposide (VP-16-213) in malignant brain tumors: A phase 11 study. J Clin Oncol 2:432-437, 1984.
33. Poisson M, Pereon Y, Chiras J: Treatment of malignant supratentorial gliomas with carboplatin (CBDCA). J Neuro-Oncol 10:139-144, 1991.
34. Twelves CJ, Ash CM, Miles DW: Activity and toxicity of car-boplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 27:481-483, 1991.
35. Levin VA, Hoffman WF, Pischer TL: BCNU, 5-fluoruracil combination therapy for recurrent malignant brain tumors. Cancer Treat Rep 62:2071-2076, 1978.
36. Levin VA, Phuphanich S, Liu H: Phase II study of combined carmustine, 5-fluoruracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. Cancer Treat Rep 70:1271-1274, 1986.
37. Schold SC, Mahaley MS, Vick NA: Phase II AZQ based chemotherapy trials in patients with high grade supratentorial astrocytoma. J Clin Oncol 5:464-470, 1987.
38. Yung WK, Harris MI, Bruner JM: Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neuro-Oncol 7:237-240, 1989.
39. Gutin PH, Wilson CB, Kumar AR: Phase II study of procarbazine, CCNU and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35:1398-1404, 1975.
40. Eagan RT, Dinapoli RP, Hermann RC: Combination carmustine and dianhidrogalactitol in the treatment of primary brain tumors recurring after irradiation. Cancer Treat Rep 66:1647-1651, 1982.
41. Levin VA, Edwards MS, Wright DC: Modified procarbazine CCNU and vincristine(PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-241, 1980.
42. Boiardi A, Silvani A, Milanesi I, et al: Efficacy of "8 drugs in one day" combination in treatment of recurrent GBM patients. J Neuro-Oncol 12:153-158, 1992.
43. Rozental JM, Robins HI, Finlay J, et al: "Eight drugs in one day" chemotherapy in postirradiated adult patients with malignant gliomas. Med Pediatr Oncol 17:471-476, 1989.
44. Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 10:766-771, 1992.
45. Coyle T, Baptista J, Winfield J, et al: Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high grade glioma in adults: A phase II study. J Clin Oncol 8:2014-2018, 1990.
46. Buckner JC, Brown LD, Cascino TL: Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neuro-Oncol. 9:249-254, 1990.
47. Jeremic B, Grujicic D, Jevremovic S, et al: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 10:1074-1079, 1992.
48. Bullard DE, Gillespie GY, Mahaley MS: Immunobiology of human gliomas. Scmin Oncol 13:94-99, 1986.
49. Hilchcock ER, Morris CS: Mononuclear cell infiltration in central portions of human astrocytomas. J Neurosurg 68:432-435, 1988.
50. Miescher S, Whileside TL, De Tribolet N: In situ characterization, clonogenic potential and anti-tumor cytolytic activity of lymphocytes infiltrating brain cancers. J Neurosurg 68:438-444, 1988.
51. De Tribolet N, Franck E, Mach JP: Monoclonal antibodies: Their application in the diagnosis and management of CNS tumours. Clin Neurosurg 34:446-456, 1988.
52. Korosue K, Takeshita I, Mannoji H: Interferon effects on multiplication, cytoplasmic protein and GFAP content, and morphology in human glioma cells. J Neuro-Oncol 1:69-73, 1983.
53. Mihara Y, Kuratsu J, Takaki S, et al: Distribution of mouse interferon-b in normal and brain tumor-bearing mice. Acta Neurochir 109:46-49, 1991.
54. Yung WKA, Prados M, Levin VA: Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: A phase I/II study. J Clin Oncol 9:1945-1950, 1991.
55. Nagai M, Arai T: Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 7:55-64, 1984.
56. von Wild KRH, Knocke TH: The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma: A phase II study. Neurosurg Rev 14:203-207, 1991.
57. Duff TA, Borden E, Bay J: Phase II trial of interferon beta for treatment of recurrent glioblastoma multiforme. J Neurosurg 64:408-413, 1986.
58. Mahaley MS, Urso MB, Whaley RA: Immunobiology of primary intracranial tumors. X. Therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63:719-725, 1985.
59. Hirakawa K, Ueda S, Nakagawa Y: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51:1976-1981, 1983.
60. Buckner JC, Brown LD, Cascino TL: Recombinant alpha-interferon and BCNU in recurrent gliomas. J Biol Response Mod 8:332-333, 1989.
61. Brandes A, Rigon A, Zampieri P, et al: Phase II trial with BCNU plus alfa 2 B interferon (IFN) in patients (PTS) with recurrent high grade gliomas. 4th Intern Congress on Anti-cancer Chemotherapy, Paris, Feb 2-3, abstract no. 235.
62. EORTC Brain Tumor Cooperative Group: Effect of AZQ(1,4-Cyclohexadiene-1,4-diacarbamic-acid-2,5-bisl-aziridynyl-d3,6- dioxodiethylester) in recurring supratentorial malignant brain gliomas: A phase II study. Eur J Clin Oncol 21:143-146, 1985.
63. Feun LG, Yung WK, Leavens ME: A phase II trial of 2,5-diaziridynyl-3-6-bis(carbohethoxy-amino)1,4-benzoquinone) AZQ: NSC 182986 in recurrent primary brain tumors. J Neuro-Oncol 2:13-17, 1984.
64. Broder LE, Carter SK: Clinical brochure BCNU (NSC-409962). Bethesda MD, 1970.
65. Wilson CB, Boldrey EB, Enot KJ: 1,3-Bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54:273-281, 1970.
66. Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9:860-864, 1991.
67. Hansen HH, Muggia FM: Treatment of malignant brain tumors with nitrosoureas. Cancer Chemother Rep 55:99-100, 1971.
68. Hoogstraten B, Gottlieb JA, Caoili E: CCNU(1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer: Phase II study. Cancer 32:38-43, 1973.
69. Taylor SA, Crowley J, Towusend J: Phase II evaluation of echi-nomycin (NSC-526417) in patients with central nervous system malignancies. J Neuro-Oncol 15:181-184, 1993.
70. Cascino TL, Brown LD, Morton FM: Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol 11:586-588, 1988.
71. Georges P, Przedboski S, Brotchi J: Effect of Hecnu in malignant supratentorial gliomas: A phase II study. J Neuro-Oncol 6:211-217, 1988.
72. Feun LJ, Savaraj N, Landy H: Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neuro-Oncol 9:159-163, 1990.
73. Jaekle KA, Mittleman A, Hill FH: Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol 8:1408-1411, 1990.
74. Elliott TE, Buckner JC, Cascino TL: Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neuro-Oncol 10:27-30, 1991.
75. Carapella CM, Iandolo B, Dalle Chiaie S: Lonidamine in primary brain tumors. Oncology 41(Suppl 1):82-85, 1984.
76. Young RC, Walker MD, Canellos GP: Initial clinical trials with methyl-CCNU 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea(McCCNU). Cancer 31:1164-1169, 1973.
77. Chamberlain MC, Prados MD, Silver PA: A phase II trial of oral melphalan in recurrent primary brain tumors. Am J Clin Oncol 11(1):52-54, 1988.
78. Stewart DJ, Hugenholz H, DaSilva VF: Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults. J Neuro-oncol 13:183-188, 1992.
79. Stewart DJ, Hugenholz H, Russel N: Phase II study of novantrone (mitoxantrone hydrocloride) in adults with III-IV astrocytomas. In: Biology of Brain Tumor, edited by MD Walker, DOT Thomas. Boston, Martinus Nijhoff Publishers, 1986, pp 411-413.
80. Levin VA, Resser KJ, McGrath L: PCNU treatment for recurrent malignant gliomas. Cancer Treat Rep 68:969-973, 1984.
81. Gerosa MA, Di Stefano H, Olivi A: VM-26 monochemotherapy trial in the treatment recurrent supratentorial gliomas: Preliminary report. Surg Neurol 15:128-131, 1981.
82. Alavi JB, Weiler CB, Bruno LA: Phase II evaluation of vindesine in the treatment of malignant glioma. Cancer Treat Rep 68:807-808, 1984.
83. Ameri A, Poisson M, Chen QM, et al: Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: A phase II study. J Neuro-Oncol 17:43-46, 1993.